Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) fell 4.7% during mid-day trading on Friday after Robert W. Baird lowered their price target on the stock from $38.00 to $35.00. The stock traded as low as $20.95 and last traded at $20.98. 27,327 shares changed hands during trading, a decline of 80% from the average session volume of 138,851 shares. The stock had previously closed at $22.01.
A number of other research firms also recently issued reports on CSTL. Stephens reiterated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, March 2nd. Scotiabank initiated coverage on Castle Biosciences in a report on Wednesday, January 4th. They set a “sector outperform” rating and a $54.00 price target on the stock. Finally, Lake Street Capital lowered their price target on Castle Biosciences from $63.00 to $41.00 in a research report on Wednesday, March 1st.
Insider Activity at Castle Biosciences
In other Castle Biosciences news, Director Daniel Bradbury sold 11,349 shares of the stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $23.30, for a total value of $264,431.70. Following the transaction, the director now owns 90,510 shares of the company’s stock, valued at $2,108,883. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Derek J. Maetzold sold 2,792 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $24.71, for a total value of $68,990.32. Following the completion of the transaction, the insider now directly owns 163,149 shares of the company’s stock, valued at approximately $4,031,411.79. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel Bradbury sold 11,349 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $23.30, for a total value of $264,431.70. Following the transaction, the director now directly owns 90,510 shares of the company’s stock, valued at approximately $2,108,883. The disclosure for this sale can be found here. Insiders have sold 34,901 shares of company stock valued at $793,954 over the last ninety days. Insiders own 7.70% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital Impact Advisors LLC raised its position in shares of Castle Biosciences by 3.5% during the 3rd quarter. Capital Impact Advisors LLC now owns 14,455 shares of the company’s stock worth $289,000 after purchasing an additional 485 shares during the last quarter. American International Group Inc. grew its stake in shares of Castle Biosciences by 5.2% during the second quarter. American International Group Inc. now owns 11,130 shares of the company’s stock valued at $244,000 after acquiring an additional 552 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Castle Biosciences by 5.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,573 shares of the company’s stock valued at $263,000 after acquiring an additional 642 shares in the last quarter. Baird Financial Group Inc. grew its stake in Castle Biosciences by 4.9% in the first quarter. Baird Financial Group Inc. now owns 14,349 shares of the company’s stock worth $644,000 after purchasing an additional 674 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Castle Biosciences by 61.2% in the third quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock worth $47,000 after acquiring an additional 691 shares during the last quarter. 82.43% of the stock is currently owned by hedge funds and other institutional investors.
Castle Biosciences Trading Down 4.7 %
The stock has a fifty day moving average price of $22.61 and a two-hundred day moving average price of $23.48.
About Castle Biosciences
Castle Biosciences, Inc is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma.